Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase II Study Evaluating Balstilimab Alone or Balstilimab in Combination With Zalifrelimab in Patients With Advanced Cervical Cancer

NCT05033132 is registered in ClinicalTrials.gov with Agenus Inc. as lead sponsor.

NCT NCT05033132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05033132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase II Study Evaluating Balstilimab Alone or Balstilimab in Combination With Zalifrelimab in Patients With Advanced Cervical Cancer
Lead sponsor
Agenus Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
October 1, 2021
Completion date
December 30, 2024
Enrollment
0 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer